Skip to main content

Advertisement

SpringerLink
Log in

Is there any use for nontraditional or alternative therapies in patients with chronic liver disease?

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

There has been a substantial increase in the use of so-called complementary and alternative therapies by patients with liver disease. Although many such modalities are available, herbal therapies are the most popular, and of these remedies, silymarin extracted from the milk thistle is most widely subscribed to as a remedy for liver diseases. Available evidence points to a potential, but unproven, benefit for this as well as other therapies based on free radical scavenger or antioxidant principles in treating patients with liver disease. These therapies deserve further investigation through experimental studies and well-controlled clinical trials. Benefits to patients from these therapies, especially to patients with established cirrhosis, are most likely to be modest and insignificant. Conversely, the hepatotoxic potential of some alternative treatments is well recognized. As practitioners educating and treating patients with liver disease, we are obliged to be informed about popular alternative therapies, understanding of our patients‘ need to be partners in their care, and open-minded to the possibility that some benefit may come from some therapies currently regarded as alternative. We need to be effective and tolerant in learning about which alternative treatments our patients are taking, so that we can monitor their effects if any and counsel appropriately against those that may cause harm.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Carroll RJ: When patients want "alternative" care ACP-ASIM Oberserver 1998, 18:1.

    Google Scholar 

  2. Eisenberg DM, Kessler RC, Foster C, et al.: Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993, 328:246 252.

    Article  PubMed  Google Scholar 

  3. Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998, 83:777–782.

    Article  PubMed  CAS  Google Scholar 

  4. Ryan JG: Who uses AIDS alternative therapies and what happens to them? Outcomes from the use of AIDS alternativ therapies among people infected with HIV: a synthesis of the medical literature [abstract]. Ahsr Fhsr Annu Meet Abstr Book 1995, 12:82–83.

    Google Scholar 

  5. Pelletier KR, Marie A, Krasner M, Haskell WL: Current trends in the integration and reimbursement of complementary and alternative medicine by managed care, insurance carriers, and hospital providers. Am J Health Promotion 1997, 12:112–122.

    CAS  Google Scholar 

  6. Eisenberg DM: Advising patients who seek alternative medical therapies. Ann Intern Med 1997, 127:61–69. This thoughtful and timely discussion presents an update on patient use of alternative therapies and outlines a step-by-step strategy whereby conventionally trained medical providers and their patients can proactively discuss the use or avoidance of alternative therapies.

    PubMed  CAS  Google Scholar 

  7. Breevoort P: The U.S. botanical market: an overview. Herbalgram 1996, 36:49–57.

    Google Scholar 

  8. Panel on Definition and Description: Defining and describing complementary and alternative medicine. CAM Research Methodology Conference, 1995. Alternative Ther Health Med 1997, 3:49–57.

    Google Scholar 

  9. Angell M, Kassirer JP: Alternative medicine: the risks of untested and unregulated remedies [editorial]. N Engl J Med 1998, 339:839–841. An impassioned editorial taking a strongly skeptical and even disparaging look at the field of alternative medicine. The authors give appropriate cautionary advice to the medical community and make a rational plea for the consistent application of the scientific method to all therapies. An important, balanced viewpoint; essential reading.

    Article  PubMed  CAS  Google Scholar 

  10. Groopman J: Medical dispatches: the shadow epidemic. The New Yorker 1998, May 11, 48–60.

  11. Weil A: Natural help for hepatitis. In Dr. Andrew Weil’s Self Healing April 1998, 1, 6–7. This issue (and certainly future ones) of the newsletter published by a prominent practitioner and teacher of alternative medicine provides insight into the curious blend of sound advice and recommendations based on unsubstantiated claims that are in wide circulation. A useful source of information on popular alternative therapeutic developments and trends.

  12. Nompleggi DJ, Bonkovsky HL: Nutritional supplementation in chronic liver disease: an analytical review. Hepatology 1994, 19:518–533.

    PubMed  CAS  Google Scholar 

  13. Corish C: Nutrition and liver disease. Nutr Rev 1997, 55:17–20. A recent and concise review of rational nutrition in liver disease.

    Article  PubMed  CAS  Google Scholar 

  14. Youngkin EQ, Israel DS: A review and critique of common herbal alternative therapies. Nurse Pract 1996, 39:43–46, 49–52.

    Google Scholar 

  15. Castleman M: The Healing Herbs: The Ultimate Guide to the Curative Power of Nature’s Medicines. New York: Banta Books; 1995.

    Google Scholar 

  16. Flora K, Hahn M, Rosen H, Benner K: Milk thistle (Silybum marianum) for the therapy of liver disease . Am J Gastroenterol 1998, 93:139–143. The best available review to date on the most popular herbal remedy used for liver disease. Good discussion of the history of its use and the available literature on its use in patients with liver disease.

    Article  PubMed  CAS  Google Scholar 

  17. Muriel P, Mourelle M: Prevention by silymarin of membrane alterations in acute CC14 liver damage. J Appl Toxicol 1990, 10:275–279.

    Article  PubMed  CAS  Google Scholar 

  18. Halim AB, el-Ahmady O, Hassab-Allah S, et al.: Biochemical effect of antioxidants on lipids and liver function in experimentally-induced liver damage. Ann Clin Biochem 1997, 34:656–663.

    PubMed  CAS  Google Scholar 

  19. Pietrangelo A, Borella F, Casalgrandi G, et al.: Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 1995, 109:1941–1949.

    Article  PubMed  CAS  Google Scholar 

  20. Valenzuela A, Garrido A: Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 1994, 27:105–112.

    PubMed  CAS  Google Scholar 

  21. Boigk G, Stroedter L, Herbst H, et al.: Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997, 26:643–649.

    Article  PubMed  CAS  Google Scholar 

  22. Fuchs EC, Weyhenmeyer R, Weiner OH: Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts. Arzneimittelforschung 1997, 47:1383–1387.

    PubMed  CAS  Google Scholar 

  23. Dehmlow C, Erhard J, de Groot H: Inhibitioin of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996, 23:749–754.

    Article  PubMed  CAS  Google Scholar 

  24. Madaus, R: Actuelle Hepatologie. Third International Symposium: Experimental and Clinical Hepatology Lübeck, Germany: Hansisches Verlagskontor; 1979.

    Google Scholar 

  25. Vogel G, Tuchweber B, Trost W, Mengs U: Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol 1984, 73:355–362.

    Article  PubMed  CAS  Google Scholar 

  26. Hruby K, Csomos G, Fuhrmann M, Thaler H: Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol 1983, 2:183–195.

    Article  PubMed  CAS  Google Scholar 

  27. Floersheim GL, Weber O, Tschumi P, Ulbrich M: Clinical deathcap (Amanita phalloides) poisoning: prognostic factors and therapeutic measures: analysis of 205 cases. Schweiz Med Wochenshr 1982, 112:1164–1177.

    CAS  Google Scholar 

  28. Szilard S, Szentgyorgyi D, Demeter I: Protective effect of Legalon in workers exposed to organic solvents. Act Med Hung 1988, 45:249–256.

    CAS  Google Scholar 

  29. Salmi HA, Sarna S: Effect of silymarin on chemical, functional, and morphological alterations of the liver: a doubleblind controlled study. Scand J Gastroenterol 1982, 17:517–521.

    Article  PubMed  CAS  Google Scholar 

  30. Buzzelli G, Mowscarella S, Giusti A, et al.: A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther 1993, 31:456–460.

    CAS  Google Scholar 

  31. Ferenci P, Dragosics B, Dittrich H, et al.: Randomized controlled trial of silymarin treatment inpatients with cirrhosis of the liver. J Hepatol 1989, 9:105–113.

    Article  PubMed  CAS  Google Scholar 

  32. Pares A, Planas R, Torres M, et al.: Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998, 28:615–621. The latest and best-designed study of silymarin in cirrhosis to date. This double-blind, placebo-controlled multicenter trial in alcoholics with liver cirrhosis established no benefit from the active drug in terms of survival or progression of liver disease. Again, no relevant side effects were observed.

    Article  PubMed  CAS  Google Scholar 

  33. Osman E, Owen JS, Burroughs AK: Review article: S-adenosyll-methionine: a new therapeutic agent in liver disease? Alimentary Pharmacol Ther 1993, 7:21–28.

    Article  CAS  Google Scholar 

  34. Kelly GS: Clinical appliations of N-acetylcysteine. Alternative Med Rev 1998, 3:114–127.

    CAS  Google Scholar 

  35. Stern E: Two cases of hepatitis C treated with herbs and supplements. J Alternative Complementary Med 1997, 3:77–82.

    CAS  Google Scholar 

  36. Batey RG, Bensoussan A, Fan YY, et al.: Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C. J Gatroenterol Hepatol 1998, 13:244 247.

    Google Scholar 

  37. Bulger EM, Helton WS: Nutrient antioxidants in gastrointestinal diseases. Gastroenterol Clin North Am 1998, 27:403–419.

    Article  PubMed  CAS  Google Scholar 

  38. Rosser BG, Gores GJ: Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology 1995, 108:252–275.

    Article  PubMed  CAS  Google Scholar 

  39. Fleming DJ, Jacques PF, Dallal GE, et al.: Dietary determinants of iron stores in a free-living elderly population: the Framingham Heart Study. Am J Clin Nutri 1998, 67:722–733.

    CAS  Google Scholar 

  40. Young IS, Trouton TG, Torney JJ, et al.: Antioxidant status and lipid peroxidation in herediatry haemochromatosis. Free Radic Biol Med 1994, 16:393–397.

    Article  PubMed  CAS  Google Scholar 

  41. Munoz SJ, Heubi JE, Balistreri WF, Maddrey WC: Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins. Hepatology 1989, 9:525–531.

    Article  PubMed  CAS  Google Scholar 

  42. Knight RE, Bourne AJ, Newton M, et al.: Neurologic syndrome associated with low levels of vitamin E in primary biliary cirrhosis. Gastroenterology 1986, 91:209–211.

    PubMed  CAS  Google Scholar 

  43. Houglu K, Venkataramani A, Lyche K, Chojkier M: A pilot study of the effects of d-alpha-tocopheral on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997, 113:1069–1073.

    Article  Google Scholar 

  44. von Herbay A, de Groot H, Hegi U, et al.: Low vitamin E content in plasma of patients with alcoholic liver disease, hemochromatosis and Wilson’s disease. J Hepatol 1994, 20:41–46.

    Article  Google Scholar 

  45. von Herbay A, Stahl W, Niederau C, Sies H: Vitamin E improves the animotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebocontrolled study. Free Radic Res 1997, 27:599–605. This paper describes a prospective, randomized, double-blind crossover design study of vitamin E administration in 23 patients with hepatitis C infection in whom interferon therapy had failed. In 11 of 23 patients the clinical parameters indicative of liver damage were improved during the phase of vitamin E treatment. Cessation of vitamin E treatment was followed by a rapid relapse of alanine aminotransferase and aspartate aminotransferase elevation, whereas retreatment led to a reproducible alanine aminotransferase decrease by 45%. The authors suggest that because vitamin E is nontoxic, the treatment of patients with hepatitis C infection refractory to alphainterferon therapy should include vitamin E as a supportive therapy.

    Google Scholar 

  46. Fiorino SW, Cusaro C, Gramenzi A, et al.: Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled controlled pilot trial. Hepatology 1998, 28:488A.

    Google Scholar 

  47. de la Maza MP, Peterman M, Bunout D, Hirsch S: Effects o long-term vitamin E supplementation in alcoholic cirrhotics. J Am Coll Nutr 1995, 14:192–196.

    PubMed  Google Scholar 

  48. Farrell GC: Drug-induced hepatic injury. J Gatroenterol Hepatol 1997, 12:S242–250. This excellent overview of drug-induced liver disease includes a useful section devoted to hepatotoxicity of herbal and folk remedies.

    CAS  Google Scholar 

  49. Picciotto A, Campo N, Brizzolar R, et al.: Chronic hepatitis induced by Jin Bu Huan. J Hepatol 1998, 28:165–167.

    Article  PubMed  CAS  Google Scholar 

  50. Ashar B, Vargo E: Shark cartilage-induced hepatitis. Ann Intern Med 1996, 125:780–781.

    PubMed  CAS  Google Scholar 

  51. Perharic L, Shaw D, Leon C, et al.: Possible association of liver damage with the use of Chinese herbal medicine for skin disease. Vet Hum Toxicol 1995, 37:562–566.

    PubMed  CAS  Google Scholar 

  52. Perron AD, Patterson JA, Yanofsky NN: Kombucha "mushroom" hepatotoxicity. Ann Emerg Med 1995, 26:660–661.

    PubMed  CAS  Google Scholar 

  53. Ko RJ: Adulterants in Asian patent medicines. N Engl J Med 1998, 339:847.

    Article  PubMed  CAS  Google Scholar 

  54. Norheim AJ: Adverse effects of acupuncture: a study of the literature for the years 1981–1994. J Alternative Complementary Med 1996, 2:291–297.

    Article  CAS  Google Scholar 

  55. Outbreak of hepatitis B associated with autohaemotherapy: update. Communciable Disease Report. Cdr Weekly 1998, 8:113.

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, UCSF Medical Center, Rm 357-S, Box 0538, 94143-0538, San Francisco, CA, USA

    Nathan M. Bass MD, PhD

Authors
  1. Nathan M. Bass MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bass, N.M. Is there any use for nontraditional or alternative therapies in patients with chronic liver disease?. Curr Gastroenterol Rep 1, 50–56 (1999). https://doi.org/10.1007/s11894-999-0087-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-999-0087-2

Keywords

Search

Navigation